ClinicalApprovalTherapy areasImmuno-oncology CTI BioPharma Receives Results of the CHMP Oral Explanation for Pacritinib in the Treatment of Myelofibrosis and Provides Development Update By Biospace News - February 1, 2019 0 7 Share on Facebook Tweet on Twitter tweet CTI BioPharma Receives Results of the CHMP Oral Explanation for Pacritinib in the Treatment of Myelofibrosis and Provides Development Update
